Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1L1 | Q9UHC9 | 9/20 | 0.56 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CDC25A | P30304 | 4/20 | 0.46 |
| ▸ | POLA1 | P09884 | 1/20 | 0.45 |
| ▸ | VDR | P11473 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.43 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16163498 | 1.00 | NPC1L1 (0.56) | NPC1L1USP2NPC1MEN1LMNA | |
| SCHEMBL14976110 | 1.00 | NPC1L1 (0.56) | NPC1L1USP2NPC1MEN1LMNA | |
| SCHEMBL20678563 | 1.00 | NPC1L1 (0.56) | NPC1L1USP2NPC1MEN1LMNA | |
| SCHEMBL14976353 | 0.99 | NPC1L1 (0.57) | NPC1L1USP2NPC1MEN1LMNA | |
| SCHEMBL16163587 | 0.99 | NPC1L1 (0.57) | NPC1L1USP2NPC1MEN1LMNA | |
| SCHEMBL14977053 | 0.99 | NPC1L1 (0.56) | NPC1L1USP2NPC1MEN1LMNA | |
| SCHEMBL16163916 | 0.99 | NPC1L1 (0.56) | NPC1L1USP2NPC1MEN1LMNA | |
| SCHEMBL16163915 | 0.96 | NPC1L1 (0.59) | NPC1L1USP2NPC1MEN1LMNA | |
| SCHEMBL14976569 | 0.96 | NPC1L1 (0.59) | NPC1L1USP2NPC1MEN1LMNA | |
| SCHEMBL14975989 | 0.96 | NPC1L1 (0.59) | NPC1L1USP2NPC1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648220-B2 | Methods for the treatment of myeloid derived suppressor cells related disorders | THE ROCKEFELLER UNIVERSITY (US) | 2023-05-16 | — | — | US | disclosed |
| US-20190029984-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648220-B2 | Methods for the treatment of myeloid derived suppressor cells related disorders | NR1H3, NR1H2, MCL1 | NPC1L1 637/4885USP2 2518/4885NPC1 146/4885 |
| US-20190029984-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | NR1H3, NR1H2, MCL1 | NPC1L1 637/4885USP2 2518/4885NPC1 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.